Company intelligence / Profile preview
DVC Stem
Grand Cayman, Cayman Islandsdvcstem.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
DVC Stem offers IRB-approved protocols using intravenous administration of 300 million culture-expanded allogeneic human umbilical cord tissue-derived mesenchymal stem cells. Their ongoing clinical study evaluates safety and effect on systemic inflammation. The company sources its MSCs from AATB-certified US donors via Vitro Biopharma’s cGMP/FDA-compliant lab in Colorado. No published pivotal trial results or regulatory approvals for specific indications as of June 2025
- Therapeutic areas
- EndocrinologyImmunologyGastroenterologyCardiovascularOphthalmologyNeurologyWomen's Health
- Modalities
- Stem cell therapyMesenchymal stem cell therapy (MSC)Allogeneic cord tissue-derived mesenchymal stem cells
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Vitro Biopharma – supplies GMP-grade MSCs from US-based laboratory
Beyond the preview
Go deeper on DVC Stem.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DVC Stem.